Ameritas Advisory Services’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$74.3K Buy
+119
New +$81K ﹤0.01% 1202
2025
Q4
Sell
-54
Closed -$30.4K 1842
2025
Q3
$30.4K Sell
54
-31
-36% -$17.5K ﹤0.01% 1275
2025
Q2
$44.7K Buy
+85
New +$47.4K ﹤0.01% 1362
2024
Q4
Sell
-373
Closed -$392K 917
2024
Q3
$392K Sell
373
-8
-2% -$8.9K 0.02% 607
2024
Q2
$400K Buy
381
+5
+1% +$4.85K 0.02% 648
2024
Q1
$357K Sell
376
-32
-8% -$30.4K 0.01% 655
2023
Q4
$371K Buy
408
+126
+45% +$104K 0.02% 498
2023
Q3
$233K Buy
+282
New +$222K 0.01% 704
2023
Q2
Sell
-268
Closed -$216K 2089
2023
Q1
$216K Sell
268
-24
-8% -$18.1K 0.01% 742
2022
Q4
$211K Sell
292
-6
-2% -$4.43K 0.01% 809
2022
Q3
$205K Buy
+298
New +$188K 0.01% 706
2022
Q2
Sell
-416
Closed -$291K 848
2022
Q1
$291K Buy
416
+86
+26% +$54.4K 0.01% 671
2021
Q4
$208K Buy
+330
New +$203K 0.01% 767

Other funds holding REGN

Ameritas Advisory Services's REGN Position: Q2 2026 in Review

Ameritas Advisory Services opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 119 shares worth $74.3K. The stake represents ﹤0.01% of the portfolio and ranks #1202 among its holdings. This is a return to the name: Ameritas Advisory Services previously reported a position in REGN as recently as Q3 2025.

Ameritas Advisory Services first reported a position in REGN in Q4 2021 and has held it in 13 quarters since. The position peaked at $400K in Q2 2024. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Ameritas Advisory Services held 119 shares of Regeneron Pharmaceuticals worth $74.3K as of Q2 2026.
  • Regeneron Pharmaceuticals was a new Ameritas Advisory Services position in Q2 2026.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Ameritas Advisory Services's portfolio in Q2 2026, its #1202 holding.
  • Ameritas Advisory Services first reported a position in Regeneron Pharmaceuticals in Q4 2021 and has held it in 13 quarters since.
  • Ameritas Advisory Services's Regeneron Pharmaceuticals position peaked at $400K in Q2 2024.
  • 1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Ameritas Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.